

REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 C.F.R. § 1.116

40. (Four times amended) A recombinant polypeptide comprising at least ten contiguous amino acids from SEQ ID NO:3, which polypeptide:

- H₁
- (i) is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3 and
 - (ii) exhibits substantially no toxicity, or substantially reduced toxicity.

55. (Amended) The recombinant polypeptide of claim 40 or 54, said polypeptide further comprising a fragment of a *Helicobacter pylori* CT polypeptide.

NE

63. (Amended) A recombinant polypeptide expressed from at least 15 contiguous nucleotides of SEQ ID NO:2, wherein said polypeptide:

- H₂
- (i) is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3 and
 - (ii) exhibits substantially no toxicity, or substantially reduced toxicity.

H₃

74. (Amended) An immunogenic, recombinant polypeptide comprising at least 10 contiguous amino acids of SEQ ID NO:3, wherein said polypeptide exhibits substantially no toxicity or substantially reduced toxicity, and wherein said polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3.

NE

76. (Amended) The recombinant polypeptide of claims 74 or 75, said polypeptide comprising an immunogenic fragment of a *Helicobacter pylori* CT polypeptide.

REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 C.F.R. § 1.116

H4
84. (Twice Amended) An immunogenic, recombinant polypeptide comprising at least 5 contiguous amino acids expressed from at least 15 contiguous nucleotides of SEQ ID NO:2, wherein said polypeptide exhibits substantially no toxicity or substantially reduced toxicity and wherein said polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide expressed by the nucleotide sequence of SEQ ID NO:2.

H5
95. (Amended) A recombinant polypeptide of a *Helicobacter pylori* cytotoxin, wherein:

- (i) said cytotoxin causes the formulation of vacuoles in eukaryotic cells;
- (ii) said recombinant polypeptide exhibits substantially no toxicity, or substantially reduced toxicity, and
- (iii) said polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3.

H6
99. (Twice Amended) A recombinant polypeptide of a *Helicobacter pylori* cytotoxin, wherein:

- (i) said cytotoxin causes the formation of vacuoles in eukaryotic cells,
- (ii) said recombinant polypeptide exhibits substantially no toxicity, or substantially reduced toxicity,
- (iii) said recombinant polypeptide is immunologically identifiable by antibodies that react specifically with the polypeptide having the amino acid sequence of SEQ ID NO:3, and
- (iv) said polypeptide is expressed from at least 15 contiguous nucleotides from SEQ ID NO:2.